06:12 AM EST, 12/24/2024 (MT Newswires) -- Merck ( MRK ) will discontinue its antibody drug, Zinplava, which was approved in 2016 to prevent the recurrence of Clostridioides difficile infections, Reuters reported late Monday, citing the US Food and Drug Administration.

Clostridioides difficile infections, often caused by prolonged antibiotic use, can lead to severe diarrhea and colon inflammation.

The report said that Zinplava will be discontinued effective Jan. 31, though no specific reason for the decision was provided.

Merck ( MRK ) and the US Food and Drug Administration did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)